NovoCure Limited

NASDAQ•NVCR

CEO: Mr. William F. Doyle

Sector: Healthcare

Industry: Medical - Instruments & Supplies

Listing Date: 2015-10-01

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.

Contact Information

Neuhofstrasse 21, Baar, 6340, Switzerland

N/A

www.novocure.com

Market Cap

$1.20B

P/E (TTM)

-8.7

56.1

Dividend Yield

52W High

$20.06

52W Low

$9.82

52W Range

Rank53Top 76.1%

2.8

F-Score

Modified Piotroski Analysis

Based on 10-year fundamentals

Weak • 2.8 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2016-2025

Financial Dashboard

Q4 2025 Data

Revenue

$174.35M+0.00%

4-Quarter Trend

EPS

-$0.22+0.00%

4-Quarter Trend

FCF

-$22.90M+0.00%

4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Net Revenue Growth Net revenues reached $655.4M USD in 2025, marking an 8% increase over the prior year's $605.2M USD.

Net Loss Reduction Net loss narrowed to $(136.2M) USD in 2025, showing operational improvement from the $(168.6M) USD loss reported in 2024.

R&D Strategic Investment Research, development, and clinical studies expenses totaled $224.5M USD, reflecting a 7% increase in strategic platform investment.

Pipeline Advancement Milestones Submitted final PMA module for Optune Mya (NSCLC brain mets); TRIDENT GBM data anticipated in Q2 2026.

Risk Factors

Operating Cash Burn Increase Cash used in operating activities increased to $(49.0M) USD for 2025, straining liquidity position compared to 2024 usage.

Key Product Sales Dependence Business heavily relies on Optune Gio sales, facing competition and limited approved indications outside of GBM currently.

Single-Source Supply Chain Dependence on single-source suppliers for critical components risks shipment delays and potential clinical study interruptions.

Regulatory Approval Uncertainty Obtaining future regulatory approvals for new indications remains costly, uncertain, and subject to significant potential delays.

Outlook

Pipeline Data Catalysts Anticipate Q1 2026 data for PANOVA-4 and Q2 2026 topline results from the TRIDENT GBM Phase 3 trial.

Global Reimbursement Expansion Actively pursuing coverage policies globally for Optune Lua and Optune Pax to expand the revenue base beyond current markets.

Cost Structure Moderation Focus on supply chain efficiencies and scaling operations to moderate G&A expense growth and achieve profitability targets.

Pancreatic Cancer Launch Execute commercialization strategy for Optune Pax following its recent February 2026 FDA approval for pancreatic cancer.

Peer Comparison

Revenue (TTM)

QDEL

$2.73B

-1.9%

TDOC

$2.53B

-1.5%

GRDN

$1.45B

+17.9%

Gross Margin (Latest Quarter)

NVCR

75.8%

-3.9pp

STAA

73.4%

+17.6pp

ESTA

70.5%

+6.2pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
EWTX	$3.52B	-20.1	-32.0%	0.7%
GRDN	$2.48B	50.4	27.5%	10.8%
NEOG	$2.05B	-3.4	-29.0%	0.0%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

4.0%

Moderate Growth

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

25%

Cash Flow Needs Attention

Deep Research

Next earnings:Apr 23, 2026

EPS:-$0.51

Revenue:$167.77M

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data